We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks ...

Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron is to collaborate with Inovio to investigate a three-way immunotherapy combination against glioblastoma multiforme (GBM), an aggressive and hard-to-treat brain tumour. Regeneron’s drug ...

As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.

which translates to an annual yield of ~0.53% - a long way behind the "Big Pharma" average yield of ~3%, but an exciting development nonetheless, as is Regeneron's promise of an "additional $3.0 ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...

“Regeneron continues to diversify our commercial ... organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening ...